Skip To Main Content
Lior Apter on Muck Rack

Lior Apter

As seen in: Oxford Academic, Dove Medical Press, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Lior Apter’s profile

Articles by Lior Apter

Healthcare resource utilization and associated cost in patients with metastatic non-small cell lung cancer treated in the immunotherapy era

|
By Sharman Moser, Lior Apter, Sarah Moser
| Oxford Academic Verified
Lung cancer, the second most prevalent cancer globally, is the primary cause of cancer-related deaths worldwide.1-3 Non-small cell lung cancer (NSCLC) constitutes approximately 80%-90% of all lung cancer cases.2,3 The five-year survival rate for patients with metastatic NSCLC (mNSCLC) was reported as only 6%-7% in a comprehensive patient database spanning the years 1999–2010.
Open in Who Shared Issue with article?

Brain metastases in HER2 positive breast cancer patients

|
By Sarah Moser, Lior Apter, Idit Livnat, Roni Ginsburg
| Dove Medical Press
Back to Journals » Breast Cancer: Targets and Therapy » Volume 16 Authors Sharman Moser S, Apter L, Livnat I, Ginsburg R, Yarden A, Drori M, Drizon A, Chodick G, Siegelmann-Danieli N Received 6 November 2023 Accepted for publication 25 January 2024 Published 6 March 2024 Volume 2024:16 Pages 105—116 DOI https://doi.org/10.2147/BCTT.S439158 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Professor Harikrishna Nakshatri...
Open in Who Shared Issue with article?

Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations

|
By Sarah Moser, Lior Apter, Orr Friedman Mazursky, Hadas Shalev
| Future Medicine Verified
Future OncologyAhead of Print Short CommunicationOpen Access Abstract Aim: To describe treatment journey and clinical outcomes after palbociclib initiation in HR+/HER2- breast cancer patients across multiple lines. Materials & methods: Adult patients (n = 559) were identified in a population-based study between January 2018 and June 2020. Results: Median follow-up time was 41.2 months. The starting dose was 125 mg for more than 85% of patients, and a third had dose reduction.
Open in Who Shared Issue with article?

Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel

|
By Sarah Moser, Thomas F. Burke, Lior Apter, Ashwini Arunachalam
| Future Medicine Verified
Lung cancer is the most common cancer diagnosed globally and the leading cause of cancer death worldwide [1]. Non-small-cell lung cancer (NSCLC) accounts for approximately 85–90% of all lung cancer with 5-year survival rate of 19% [2]. Until 2014, platinum-based doublet chemotherapy has been the standard of care for metastatic NSCLC (mNSCLC) with only limited survival benefit [3].
Open in Who Shared Issue with article?
Show More